Straumann Group (STMN) Q2 2025 earnings summary

Executive summary

• Revenue reached CHF 1.3 billion in H1 2025, with Q2 contributing CHF 667.5 million and organic growth of 10.2% in H1 and 9.3% in Q2, despite currency headwinds.

• Core EBIT margin was 26.6% (27.3% at constant currency), and core net profit rose 16% to CHF 265 million at constant currencies.

• Strong performance across all regions, with double-digit growth in Asia-Pacific and Latin America, and consistent growth in EMEA.

• Digital innovation and new product launches, including iEXCEL and MIDAS 3D printer, are driving market share gains and segment momentum.

• Regulatory approval for premium implant production in China and the Shanghai campus license strengthen long-term growth prospects.

Financial highlights

• H1 2025 revenue: CHF 1,348m (+10.2% organic); Q2 revenue: CHF 667.5m (+9.3% organic).

• Core gross margin: 72.1% (down 50 bps YoY due to FX); core EBIT margin: 26.6% (27.3% at constant FX); IFRS EBIT margin: 24.4%.

• Free cash flow for H1 was CHF 113 million (8.4% of revenue), down year-on-year due to higher CapEx.

• Core net profit reached CHF 265 million (margin 19.7%), up 16% at constant currency; basic EPS CHF 1.66.

• Cash position at end of June: CHF 247 million; dividend paid: CHF 151.3 million.

Outlook and guidance

• 2025 outlook confirmed: high single-digit organic revenue growth and 30–60 bps core EBIT margin improvement at constant 2024 FX rates.

• Growth ambition for 2030 reaffirmed; expects to continue outgrowing the market.

• Guidance incorporates potential VBP 2.0 impact in China and ongoing tariff headwinds.

• Ongoing investments in production capacity, digital transformation, and clinician training to support growth.

• Broad geographic presence and diversified manufacturing footprint provide resilience against regional and geopolitical risks.